Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria Bioscience (NASDAQ:LEXX) has announced its strategic pursuit of developing the world's first oral version of liraglutide using their DehydraTECH technology. The company has filed patent applications following successful animal studies that showed DehydraTECH-liraglutide outperformed Rybelsus control group by 11.53% in blood sugar control and 11.13% in body weight control by week 12.
The company has received ethics board approval to commence human pilot study GLP-1-H25-5, comparing oral DehydraTECH-processed Saxenda to conventional injected liraglutide. This initiative is part of Lexaria's broader strategy to enter the GLP-1 weight loss and diabetes control market, which has grown from $300 million in 2018 to approximately $30 billion in 2024.
Currently, liraglutide is only available in injectable form under Saxenda and Victoza brands by Novo Nordisk, generating $849 million in H1 2024 and $1.6 billion in recent annual revenue respectively.
Lexaria Bioscience (Nasdaq: LEXX) has been granted two new patents from the United States Patent and Trademark Office for its DehydraTECH enhanced processing technology in epilepsy treatment. These represent the company's 5th and 6th US patents in its patent family #24, 'Compositions and Methods for Treating Epilepsy,' bringing Lexaria's total granted patents to 48.
The patents, set to expire in 2043 unless extended, build upon previous research demonstrating that DehydraTECH-CBD could mitigate epileptic seizures in rodents and showed superior bloodstream absorption compared to Epidiolex, a commercial cannabinoid-based anti-seizure medication.
Lexaria Bioscience (Nasdaq:LEXX) has initiated a groundbreaking rodent biodistribution study to track DehydraTECH-processed semaglutide. The study aims to compare the biodistribution patterns of DehydraTECH-processed semaglutide against conventional Rybelsus®-like formulations.
The research utilizes fluorescently tagged semaglutide (FTS) in Sprague-Dawley rats, examining distribution patterns in key tissues including brain, pancreas, lung, kidney, liver, and heart. The study incorporates two test formulations: one mimicking Rybelsus® without DehydraTECH, and another using Lexaria's patented DehydraTECH process.
The study employs immunofluorescence methodology to detect GLP-1 receptor binding, providing detailed insights into tissue distribution and localization patterns. Results will be used to enhance communications with potential industry partners.
Lexaria Bioscience (NASDAQ:LEXX) has provided updates on its ongoing Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia. The company has completed its submission to the human research ethics committee (HREC) to add Study Arm 5, which will evaluate the performance of its DehydraTECH-tirzepatide formulation. This addition follows positive findings from their previous Human Pilot Study #3.
The company has received HREC approval for all 4 original arms across all participating clinical sites, following earlier approval for the lead clinical site. Clinical test article manufacturing has been completed. The company's previous Human Pilot Study #3 demonstrated comparable results in blood glucose reduction and insulin levels, along with significantly reduced adverse events when Eli Lilly's Zepbound® was processed with Lexaria's DehydraTECH™ technology.
Lexaria Bioscience (NASDAQ:LEXX) released its annual CEO letter highlighting significant achievements in 2024, particularly in GLP-1 drug delivery technology. The company raised $13.4M net through equity raises and warrant exercises, while its stock price increased 68% during the year.
Key developments included successful completion of multiple studies demonstrating positive results with DehydraTECH technology for GLP-1 drugs: semaglutide, tirzepatide, and liraglutide. Notable outcomes included 18.8% higher semaglutide levels and 60% reduction in adverse events compared to Rybelsus®.
The company launched its first Phase 1b registrational study in Australia and received FDA clearance for a Phase 1b hypertension study. Lexaria secured 8 additional patents, expanding its portfolio to 46 patents worldwide, and entered into a Material Transfer Agreement with a pharmaceutical company for pre-clinical evaluation of DehydraTECH technology.
Lexaria Bioscience Corp. (LEXX) has received independent ethics board approval for its human pilot study GLP-1-H25-5, which will compare oral DehydraTECH-liraglutide to injectable Saxenda®. This follows successful animal studies where oral DehydraTECH-liraglutide showed a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline.
The study will involve 8-10 healthy volunteers to demonstrate safety and pharmacokinetic performance of orally dosed DehydraTECH-liraglutide. Positive results could lead to a Phase I registered trial. Liraglutide, currently sold only as injectable Saxenda® and Victoza®, generated US$849 million (Saxenda®) in H1 2024 and US$1.6 billion (Victoza®) in recent annual revenue.
Lexaria Bioscience (NASDAQ:LEXX) announced partial results from study GLP-1-H24-3, comparing oral DehydraTECH-tirzepatide to injectable Zepbound®. The oral version showed 47% fewer total adverse events and 54% fewer gastrointestinal-related events compared to the injectable version.
The oral formulation demonstrated comparable blood glucose reduction and insulin secretion levels to injected Zepbound®. Blood glucose levels decreased from 88.2±9.0 to 83.2±5.7 mg/dL for oral DehydraTECH-tirzepatide, compared to 87.8±11.3 to 81.7±4.0 mg/dL for injected Zepbound®. At peak times, the oral version induced insulin levels up to 100% higher than the injection.
Based on these promising results, Lexaria plans to add a fifth study arm to its ongoing 12-week human study in Australia (GLP-1-H24-4), testing oral DehydraTECH-tirzepatide at current and doubled doses.
Lexaria Bioscience (Nasdaq: LEXX) has initiated dosing in its Phase 1b, 12-week chronic study GLP-1-H24-4. The study aims to evaluate whether Lexaria's DehydraTECH technology enhances the safety and effectiveness of existing GLP-1 drugs. The trial includes multiple arms testing different combinations: DehydraTECH-CBD capsules, DehydraTECH-semaglutide capsules, a combination of both, Rybelsus® tablets as positive control, and potentially DehydraTECH-tirzepatide capsules. The study will be conducted across seven clinical sites in Australia and is expected to be recognized as a Phase 1b registrational study by the FDA.
Lexaria Bioscience Corp. (Nasdaq:LEXX) has announced the formation of a new Scientific Advisory Board (SAB) to guide its drug delivery platform technology development. The SAB will be chaired by John Docherty, Lexaria's President and Chief Scientific Officer, and includes three distinguished members: Dr. Michael Gibson, CEO of Baim and PERFUSE research institutes at Harvard Medical School; Dr. Karen Aust, Senior Director of Regulatory Affairs at G&L Healthcare Advisors; and Prof. Philip Ainslie, Research Chair at the University of British Columbia. The board will provide expertise in pharmaceutical development, clinical testing, and Chemistry Manufacturing and Controls (CMC) characterization, supporting Lexaria's commercialization efforts for its DehydraTECH technology.
Lexaria Bioscience (NASDAQ:LEXX) has appointed Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson, a highly cited interventional cardiologist and Harvard Medical School researcher, will work directly with President John Docherty to expand applications of Lexaria's DehydraTECH drug delivery platform in GLP-1 and hypertension.
As CEO of the Baim and PERFUSE research institutes at Harvard Medical School, Dr. Gibson has led over 1,250 studies and 70 FDA submissions. His institutes have published 5,500 manuscripts and operate across 7,000 sites in 57 countries. His research has been cited over 170,000 times, and he was named one of the Fifty Most Influential Voices in Healthcare by Medika Life in 2021.
FAQ
What is the current stock price of Lexaria Bioscience (LEXX)?
What is the market cap of Lexaria Bioscience (LEXX)?
